Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Accured Expenses (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Change in Accured Expenses for 7 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 457.97% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 199.32% increase, with the full-year FY2025 number at $1.0 million, up 199.32% from a year prior.
  • Change in Accured Expenses was $2.3 million for Q4 2025 at Fulcrum Therapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.8 million in Q2 2022 to a low of -$4.5 million in Q3 2022.
  • A 5-year average of $83650.0 and a median of $679000.0 in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 2313.0% in 2021; the steepest drop was 2115.38% in 2021.
  • Fulcrum Therapeutics' Change in Accured Expenses stood at -$795000.0 in 2021, then surged by 296.48% to $1.6 million in 2022, then tumbled by 41.81% to $909000.0 in 2023, then crashed by 170.41% to -$640000.0 in 2024, then soared by 457.97% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Change in Accured Expenses are $2.3 million (Q4 2025), $1.5 million (Q3 2025), and $587000.0 (Q2 2025).